Why the study?
Does angiotensin receptor antagonists improve renoprotection and mortality compared to angiotensin converting enzyme inhibitors in patients with progressive renal disease?
Does angiotensin receptor antagonists improve renoprotection and mortality compared to angiotensin converting enzyme inhibitors in patients with progressive renal disease?
ACE inhibitors remain the standard of care for progressive renal disease, as the interchangeability or synergistic benefits of AT1 receptor antagonists require further clinical trials.
No takes yet. Share an insight, caveat, or question.
ACE inhibitors remain first-line in progressive renal disease; leaves open whether AT1 antagonists confer added renoprotection or survival benefit.
Kevin McLaughlin (1999) studied this question.